The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar ...
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry The first and only TMS company to establish comprehensive standard...
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 Early prediction of nonresponse abstract selected for oral presentation as a prest...
MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...
Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older...
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President, Chief Executive Officer Stev...
Neuronetics (STIM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.38 per share a year ago....
MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of trans...
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the...